Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;10(2):127-135.
doi: 10.1177/1756285616677005. Epub 2016 Nov 16.

Botulinum toxin in the management of chronic migraine: clinical evidence and experience

Claus M Escher  1 , Lejla Paracka  2 , Dirk Dressler  2 , Katja Kollewe  3
Affiliations
Review

Botulinum toxin in the management of chronic migraine: clinical evidence and experience

Claus M Escher et al. Ther Adv Neurol Disord. 2017 Feb.

Abstract

Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.

Keywords: Botox®; botulinum neurotoxin; chronic daily headache; chronic migraine; onabotulinumtoxinA.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: CE states that he has no conflict of interest. LP received travel grants from Ipsen (Boulogne-Billancourt, France) and Merz (Frankfurt/M, Germany). DD received honoraria for consultations from Allergan (Irvine, California, USA), Bayer (Leverkusen, Germany), Eisai (Tokio, Japan), IAB-Interdisciplinary Working Group for Movement Disorders (Hamburg, Germany), Ipsen, Merz and UCB (Monheim, Germany). He is shareholder of Allergan and holds several patents on botulinum toxins. KK received travel grants and honoraria for lectures from Allergan, Ipsen and Merz.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adams A.M., Serrano D., Buse D.C., Reed M.L., Marske V., Fanning K.M., et al. (2015) The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 35: 563–578. - PMC - PubMed
    1. Ahmed F., Zafar H., Buture A., Khalil M. (2015) Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus 4: 589. - PMC - PubMed
    1. Aoki K. (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl. 1): S9–15. - PubMed
    1. Aurora S., Dodick D., Diener H., DeGryse R., Turkel C., Lipton R., et al. (2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129: 61–70. - PMC - PubMed
    1. Aurora S., Dodick D., Turkel C., DeGryse R., Silberstein S., Lipton R., et al. (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalgia 30: 793–803. - PubMed

LinkOut - more resources